ClinicalTrials.gg
CompletedNCT05469113Updated Dec 11, 2025Results posted

A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants

A Phase 1 interventional study of Repaglinide and Selpercatinib in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 3 years 5 months after the study started (first participant enrolled Jan 2019, registered Jul 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to assess the effect of selpercatinib on how fast repaglinide gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. Information about safety and tolerability will be collected. The study will last up to 12 days.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) ≥ 18.0 and ≤ 32.0 kilograms per meter squared (kg/m²) and had a minimum weight of at least 50 kg at screening
  • Have normal blood pressure, pulse rate, (ECG), and blood and urine laboratory test results that are acceptable for the study
  • (Hb) A1c value \< 6.5 % at screening and fasting glucose ≤ 126 mg/dL.
  • Males who are capable of fathering a child must agree to use one of the following methods of from the time of the dose administration through 6 months after the last dose
  • Female of non- only or must have undergone sterilization procedures at least 6months prior to the first dosing

Exclusion criteria

Exclusion Criteria:

  • History or presence of diabetes or history of prior episode(s) of hypoglycemia.
  • Estimated \<90 mL/min at Screening or Check-in (Day -1, Period 1)
  • Unable to refrain from or anticipates the use of any drug, including prescription and non prescription medications, herbal remedies, or vitamin supplements for 14 days prior to the first dosing and through EOT or ET. After first dosing, acetaminophen (up to 2 g per 24 hours) may be administered at the discretion of the PI or designee
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Period 1: Repaglinide

    * Day 1: Participants received single dose of 0.5 mg repaglinide tablet.

    Drug: Repaglinide

  • Experimental
    Period 2: Selpercatinib + Repaglinide

    * Day 1 to Day 9: Participants received 160 mg Selpercatinib capsule twice daily (BID). * Day 10: Participant received 160 mg Selpercatinib capsules BID co-administered with a single oral dose of 0.5 mg Repaglinide tablet on the morning of Day 10.

    Drug: Repaglinide · Drug: Selpercatinib

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Repaglinide

    Time frame: Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)

  2. PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Repaglinide

    Time frame: Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)

  3. PK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Repaglinide

    Time frame: Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)

  4. PK: Maximum Observed Concentration (Cmax) of Repaglinide

    Time frame: Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)

  5. PK: Time to Reach Maximum Observed Concentration (Tmax) of Repaglinide

    Time frame: Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)

  6. PK: Apparent Terminal Elimination Rate Constant (Kel) of Repaglindide

    Time frame: Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)

  7. PK: Apparent First-order Terminal Elimination Half-life (t½) of Repaglinide

    Time frame: Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)

  8. PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Repaglinide

    PK: CL/F of Repaglinide

    Time frame: Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)

  9. PK: Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Repaglinide

    Time frame: Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)

Secondary outcomes

  1. PK: Area Under the Concentration-time Curve, From Time 0 to the 12 Hour (AUC0-12) of Selpercatinib

    Time frame: Period 2: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)

  2. PK: Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib

    Time frame: Period 2: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)

  3. PK: Maximum Observed Concentration (Cmax) of Selpercatinib

    Time frame: Period 2: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)

  4. PK: Time to Reach Maximum Observed Concentration (Tmax) of Selpercatinib

    Time frame: Period 2: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)

  5. PK: Area Under the Concentration-time Curve During a Dosing Interval (Tau) at Steady State (AUCtau) of Selpercatinib

    Time frame: Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)

  6. PK: Maximum Observed Concentration at Steady-state (Cmax,ss) of Selpertcatinib

    Time frame: Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)

  7. PK: Concentration Observed at the End of the Dosing Interval (Ctrough) of Selpercatinib

    Time frame: Period 2: Predose at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9

  8. PK: Time to Reach Maximum Observed Concentration at Steady-state (Tmax,ss) of Selpercatinib

    Time frame: Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)

  9. PK: Apparent Total Plasma Clearance at Steady State After Oral/Extravascular Administration (CL,ss/F) of Selpercatinib

    Time frame: Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)

07

Results

Posted Dec 11, 2025

Participant flow

Period 1
Participant flow — Period 1
MilestonePeriod 1: RepaglinidePeriod 2: Selpercatinib + Repaglinide
Started160
Safety analysis population (received at least one dose of study drug)160
Completed160
Not completed00
Period 2
Participant flow — Period 2
MilestonePeriod 1: RepaglinidePeriod 2: Selpercatinib + Repaglinide
Started016
Safety analysis population (received at least one dose of study drug)016
Completed013
Not completed03
Withdrew: Adverse event03

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Repaglinide
Time frame:
Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Repaglinide
nanogram*hour per milliliter (ng*h/mL)Period 1: RepaglinidePeriod 2: Selpercatinib + Repaglinide
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Repaglinide9.409 ± 57.126.87 ± 53.2
PrimaryPK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Repaglinide
Time frame:
Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Repaglinide
nanogram*hour per milliliter (ng*h/mL)Period 1: RepaglinidePeriod 2: Selpercatinib + Repaglinide
PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Repaglinide10.15 ± 51.327.31 ± 53.6
PrimaryPK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Repaglinide
Time frame:
Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)
Reported as:
Geometric mean · percent AUC extrapolation
PK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Repaglinide
percent AUC extrapolationPeriod 1: RepaglinidePeriod 2: Selpercatinib + Repaglinide
PK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Repaglinide1.256 ± 43.81.258 ± 85.8
PrimaryPK: Maximum Observed Concentration (Cmax) of Repaglinide
Time frame:
Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
PK: Maximum Observed Concentration (Cmax) of Repaglinide
nanogram per milliliter (ng/mL)Period 1: RepaglinidePeriod 2: Selpercatinib + Repaglinide
PK: Maximum Observed Concentration (Cmax) of Repaglinide6.600 ± 77.412.11 ± 42.7
PrimaryPK: Time to Reach Maximum Observed Concentration (Tmax) of Repaglinide
Time frame:
Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)
Reported as:
Geometric mean · hours
PK: Time to Reach Maximum Observed Concentration (Tmax) of Repaglinide
hoursPeriod 1: RepaglinidePeriod 2: Selpercatinib + Repaglinide
PK: Time to Reach Maximum Observed Concentration (Tmax) of Repaglinide0.623 ± 47.30.854 ± 42.5
PrimaryPK: Apparent Terminal Elimination Rate Constant (Kel) of Repaglindide
Time frame:
Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)
Reported as:
Geometric mean · One per hour (1/h)
PK: Apparent Terminal Elimination Rate Constant (Kel) of Repaglindide
One per hour (1/h)Period 1: RepaglinidePeriod 2: Selpercatinib + Repaglinide
PK: Apparent Terminal Elimination Rate Constant (Kel) of Repaglindide0.2406 ± 27.90.2036 ± 36.2
PrimaryPK: Apparent First-order Terminal Elimination Half-life (t½) of Repaglinide
Time frame:
Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)
Reported as:
Geometric mean · hours
PK: Apparent First-order Terminal Elimination Half-life (t½) of Repaglinide
hoursPeriod 1: RepaglinidePeriod 2: Selpercatinib + Repaglinide
PK: Apparent First-order Terminal Elimination Half-life (t½) of Repaglinide2.881 ± 27.93.405 ± 36.2
PrimaryPK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Repaglinide

PK: CL/F of Repaglinide

Time frame:
Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)
Reported as:
Geometric mean · Liter per Hour (L/h)
PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Repaglinide
Liter per Hour (L/h)Period 1: RepaglinidePeriod 2: Selpercatinib + Repaglinide
PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Repaglinide49.26 ± 51.318.31 ± 53.6
PrimaryPK: Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Repaglinide
Time frame:
Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)
Reported as:
Geometric mean · Liter (L)
PK: Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Repaglinide
Liter (L)Period 1: RepaglinidePeriod 2: Selpercatinib + Repaglinide
PK: Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Repaglinide204.8 ± 53.689.92 ± 64.9
SecondaryPK: Area Under the Concentration-time Curve, From Time 0 to the 12 Hour (AUC0-12) of Selpercatinib
Time frame:
Period 2: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)
Reported as:
Geometric mean · ng*h/mL
PK: Area Under the Concentration-time Curve, From Time 0 to the 12 Hour (AUC0-12) of Selpercatinib
ng*h/mLPeriod 2: Selpercatinib + Repaglinide
PK: Area Under the Concentration-time Curve, From Time 0 to the 12 Hour (AUC0-12) of Selpercatinib8424 ± 56.6
SecondaryPK: Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib
Time frame:
Period 2: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)
Reported as:
Geometric mean · ng*h/mL
PK: Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib
ng*h/mLPeriod 2: Selpercatinib + Repaglinide
PK: Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib8396 ± 56.7
SecondaryPK: Maximum Observed Concentration (Cmax) of Selpercatinib
Time frame:
Period 2: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)
Reported as:
Geometric mean · ng/mL
PK: Maximum Observed Concentration (Cmax) of Selpercatinib
ng/mLPeriod 2: Selpercatinib + Repaglinide
PK: Maximum Observed Concentration (Cmax) of Selpercatinib1476 ± 66.3
SecondaryPK: Time to Reach Maximum Observed Concentration (Tmax) of Selpercatinib
Time frame:
Period 2: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)
Reported as:
Geometric mean · hours
PK: Time to Reach Maximum Observed Concentration (Tmax) of Selpercatinib
hoursPeriod 2: Selpercatinib + Repaglinide
PK: Time to Reach Maximum Observed Concentration (Tmax) of Selpercatinib1.553 ± 25.9
SecondaryPK: Area Under the Concentration-time Curve During a Dosing Interval (Tau) at Steady State (AUCtau) of Selpercatinib
Time frame:
Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)
Reported as:
Geometric mean · ng*h/mL
PK: Area Under the Concentration-time Curve During a Dosing Interval (Tau) at Steady State (AUCtau) of Selpercatinib
ng*h/mLPeriod 2: Selpercatinib + Repaglinide
PK: Area Under the Concentration-time Curve During a Dosing Interval (Tau) at Steady State (AUCtau) of Selpercatinib33960 ± 45.0
SecondaryPK: Maximum Observed Concentration at Steady-state (Cmax,ss) of Selpertcatinib
Time frame:
Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)
Reported as:
Geometric mean · ng/mL
PK: Maximum Observed Concentration at Steady-state (Cmax,ss) of Selpertcatinib
ng/mLPeriod 2: Selpercatinib + Repaglinide
PK: Maximum Observed Concentration at Steady-state (Cmax,ss) of Selpertcatinib4082 ± 40.8
SecondaryPK: Concentration Observed at the End of the Dosing Interval (Ctrough) of Selpercatinib
Time frame:
Period 2: Predose at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9
Reported as:
Mean · ng/mL
PK: Concentration Observed at the End of the Dosing Interval (Ctrough) of Selpercatinib
ng/mLPeriod 2: Selpercatinib + Repaglinide
Day 1983.2 ± 225.43
Day 21509 ± 362.03
Day 31664 ± 529.60
Day 41842 ± 657.65
Day 51971 ± 642.36
Day 62039 ± 780.35
Day 72160 ± 771.22
Day 82034 ± 635.04
Day 92085 ± 762.09
SecondaryPK: Time to Reach Maximum Observed Concentration at Steady-state (Tmax,ss) of Selpercatinib
Time frame:
Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)
Reported as:
Geometric mean · hours
PK: Time to Reach Maximum Observed Concentration at Steady-state (Tmax,ss) of Selpercatinib
hoursPeriod 2: Selpercatinib + Repaglinide
PK: Time to Reach Maximum Observed Concentration at Steady-state (Tmax,ss) of Selpercatinib1.888 ± 29.6
SecondaryPK: Apparent Total Plasma Clearance at Steady State After Oral/Extravascular Administration (CL,ss/F) of Selpercatinib
Time frame:
Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)
Reported as:
Geometric mean · Liter per Hours (L/h)
PK: Apparent Total Plasma Clearance at Steady State After Oral/Extravascular Administration (CL,ss/F) of Selpercatinib
Liter per Hours (L/h)Period 2: Selpercatinib + Repaglinide
PK: Apparent Total Plasma Clearance at Steady State After Oral/Extravascular Administration (CL,ss/F) of Selpercatinib4.711 ± 45.0

Adverse events

Collected over Baseline to Follow-up (up to Day 2 for Period 1; up to Day 11 for Period 2). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 1: Repaglinide (Day 1)0/16 (0%)0/16 (0%)7/16 (43.8%)
Period 2: Selpercatinib (Day 1 to Day 9)0/16 (0%)0/16 (0%)7/16 (43.8%)
Period 2: Selpercatinib + Repaglinide (Day 10)0/13 (0%)0/13 (0%)11/13 (84.6%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPeriod 1: Repaglinide (Day 1)Period 2: Selpercatinib (Day 1 to Day 9)Period 2: Selpercatinib + Repaglinide (Day 10)
Blood glucose decreasedInvestigations5/160/168/13
HypoglycaemiaMetabolism and nutrition disorders1/160/163/13
HeadacheNervous system disorders0/162/162/13
PainGeneral disorders0/160/161/13
NauseaGastrointestinal disorders0/160/161/13
CoughRespiratory, thoracic and mediastinal disorders0/160/161/13
Electrocardiogram QT prolongedInvestigations0/161/160/13
DizzinessNervous system disorders0/161/160/13
TremorNervous system disorders1/160/160/13
FatigueGeneral disorders0/161/160/13

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)All Participants
Mean37.2 ± 10.62
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female3
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino9
Not Hispanic or Latino7
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White15
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)All Participants
United States16
08

Study locations

1 site
  • Celerion
    Tempe, Arizona 85283, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Mar 2019, 1 month.

Results were first posted in Dec 2025, 6 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2022
First posted
Jul 21, 2022
StartActual
Jan 29, 2019
Primary completionActual
Mar 5, 2019
CompletionActual
Mar 5, 2019
Results first posted
Dec 11, 2025
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05469113
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Jul 21, 2022
Start date
Jan 29, 2019
Primary completion
Mar 5, 2019
Completion
Mar 5, 2019
Results posted
Dec 11, 2025
Last update
Dec 11, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Repaglinide

Start the discussion